[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-hypertension":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,76,103,128,145,161,177,198,220,241,265,287,308,329,350,376,399,436],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100575896","childhood-onset-essential-hypertension-natural-history-study-100575896",false,"NCT06778239","Childhood-Onset Essential Hypertension Natural History Study","Natural History Study to Determine Childhood-Onset Essential Hypertension Etiology","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an affected individual must meet one of the following criteria:\n\n* Age 2-12 years at time of enrollment with a BP of at least \\>95th percentile or 120\u002F80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging\u002Fbody measurements (e.g., renal ultrasound)\n* Age 13-17 years at time of enrollment with a BP of at least 130\u002F80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging\u002Fbody measurements (e.g., renal ultrasound)\n* Age 18 years or more at time of enrollment with a medical history of meeting the criteria outlined in affected individual inclusion criteria 1 or 2, depending on age at diagnosis (verified via medical record review) and a willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history\n\nTo be eligible to participate in this study, an unaffected individual must meet all of the following criteria:\n\n* First-degree relative to a proband (first identified affected family member) in the study\n* Willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history\n\nTo be eligible to participate in this study, an individual with a candidate variant (regardless of known COEH status) must meet all of the following criteria:\n\n* History of clinical and\u002For research genomic interrogation\n* Positive genomic interrogation test result for candidate variant identified in earlier stages of study or in prior studies performed by study team\n* Willingness to provide information related to family and medical history, provide access to relevant medical records, undergo physical exam, and undergo imaging\u002Fbody measurements (if 2-17 years of age and evidence of COEH exists)\n\nEXCLUSION CRITERIA:\n\nAn affected individual who meets any of the following criteria will be excluded from participation in this study:\n\n* BMI \\>95th percentile\n* Evidence that hypertension is secondary to a known condition (e.g., chronic kidney disease, aortopathy, sleep apnea, etc.)\n* Impaired decision-making capability, with or without a legally-authorized representative\n\nAn unaffected individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Prior or current diagnosis of COEH\n* Second-degree or greater relationship to proband\n* Impaired decision-making capability, with or without a legally-authorized representative\n\nAn individual with a candidate variant (regardless of known COEH status) who meets any of the following criteria will be excluded from participation in this study:\n\n* No prior genomic interrogation findings available for the study team to review to confirm positive candidate variant status\n* Impaired decision-making capability, with or without a legally-authorized representative","ALL","2 Years","99 Years",{"count":20,"type":21},2300,"ESTIMATED","OBSERVATIONAL","Background:\n\nChildhood-onset essential hypertension (COEH) is high blood pressure that develops in children and teens. High blood pressure is a major risk factor for heart disease. COEH is more likely to be caused by changes in genes rather than by factors like stress or diet. Researchers want to learn more about how changes in genes relate to COEH. They hope to use that information to develop better treatments for children with high blood pressure.\n\nObjective:\n\nThis natural history study will look for genes and gene changes that may lead to COEH.\n\nEligibility:\n\nPeople aged 2 years and older with COEH or who had COEH when they were children. Healthy relatives of those with COEH are also needed.\n\nDesign:\n\nParticipants will have one clinic visit per year for up to 10 years. All participants will have a physical exam. They will provide samples of blood and urine. At their first visit, they will have a swab (like a Q-tip) rubbed between their gums and cheeks. They may agree to having a skin biopsy; a piece of skin about the size of a pencil eraser will be removed.\n\nAffected participants aged 2 to 17 years old will have additional tests:\n\n* They will have sensors placed on their skin to look at their blood vessels and see how blood is moving in their bodies.\n* They will lie or stand while a machine measures the amount of fat and muscle in their bodies.\n* They will have an ultrasound; a wand will be rubbed against their skin to take pictures of their kidneys.\n\nOther things are optional for all participants:\n\n* They may have photographs taken of their bodies.\n* They may have tests of their heart function.\n* They may have different types of imaging scans....",[25,26],"Hypertension","Essential Hypertension",[28,29,30,31,25],"Blood Pressure","Pediatric","childhood hypertension","ESSENTIAL HYPERTENSION","RECRUITING","2026-05-23",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2025-05-30",{"date":40,"type":21},"2034-12-09",{"name":42,"class":43},"National Human Genome Research Institute (NHGRI)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100638635","safety-and-efficacy-evaluation-of-non-invasive-temporal-interference-stimulation-for-blood-pressure-modulation-in-patients-with-mild-essential-hypertension-100638635","NCT07577323","Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension","Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension: A Prospective, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged between 30 and 65 years old.\n2. Office blood pressure with systolic blood pressure (SBP) 140-159 mmHg and\u002For diastolic blood pressure (DBP) 90-99 mmHg.\n3. No intake of any antihypertensive drugs or have discontinued antihypertensive medication for at least 3 months prior to randomization; no intention to receive any other antihypertensive therapy within the 15-week study period.\n4. Written informed consent has been obtained from the subject or their legally authorized representative after being informed of the potential risks.\n\nExclusion Criteria:\n\n1. Known or suspected secondary hypertension.\n2. Contraindications to TI treatment or sham TI treatment, including intracranial metal implants (e.g., pacemaker, ventriculoperitoneal shunt, vascular clip), craniocerebral surgery within the last 6 months, history of intracranial tumor or hemorrhage; skin damage, infection, eczema or allergy at the stimulation site (frontal\u002Ftemporal region); severe skin diseases (e.g., psoriasis).\n3. Subjects with high risk of cerebrovascular disease indicated by cranial magnetic resonance imaging.\n4. History of myocardial infarction or cerebral infarction.\n5. Atrial fibrillation or other severe arrhythmias, such as severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia.\n6. Severe or unstable medical conditions, including severe hepatic dysfunction (defined as alanine transaminase or aspartate transaminase level more than 2 times the upper limit of normal), severe renal dysfunction (defined as serum creatinine level more than 1.5 times the upper limit of normal), and severe heart failure (New York Heart Association Class III and IV).\n7. Females who are pregnant, breastfeeding, or planning to become pregnant within one year.\n8. Individuals unable to cooperate due to mental illness or other reasons.\n9. Participants enrolled in other clinical trials within 3 months prior to randomization.\n10. Participants deemed ineligible for this trial for other reasons determined by the investigator.","30 Years","65 Years",{"count":55,"type":21},60,"INTERVENTIONAL",[58],"NA","The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for blood pressure modulation in patients with mild essential hypertension.",[26],[62,63,64],"essential hypertension","temporal interference stimulation","TI","NOT_YET_RECRUITING","2026-05-04",{"date":68,"type":36},"2026-05-11",{"date":70,"type":21},"2026-05-06",{"date":72,"type":21},"2027-12-31",{"name":74,"class":75},"Xuanwu Hospital, Beijing","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":53,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100625552","remidep-hta-program-for-hypertension-remission-and-medication-deprescription-100625552","NCT07424118","REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription","Efficacy of the REMIDEP-HTA Program in Hypertension Remission and Pharmacological Deprescription: A Multicenter Randomized Clinical Trial","REMIDEP-HTA","Inclusion Criteria \\\u003Cbr\\>\\\u003Cbr\\> Men and women aged 40 to 65 years. \\\u003Cbr\\>\\\u003Cbr\\> Confirmed diagnosis of chronic essential hypertension established at least 6 months prior to enrollment.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Stable antihypertensive pharmacological treatment for at least 3 months prior to enrollment, with no changes in medications or dosages.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Blood pressure at screening ≤ 160\u002F100 millimeters of mercury (mmHg). \\\u003Cbr\\>\\\u003Cbr\\> Ability and willingness to comply with the 12-week behavioral intervention, attend scheduled coaching sessions (60-minute group sessions and 10-minute rescue sessions), perform home blood pressure monitoring, and attend clinical visits according to the study schedule.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Access to an electronic device with internet connectivity sufficient to participate in virtual coaching sessions and to receive and use the program digital materials.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Exclusion Criteria \\\u003Cbr\\>\\\u003Cbr\\> Secondary hypertension. \\\u003Cbr\\>\\\u003Cbr\\> Use of antihypertensive medications for indications other than treatment of hypertension, or use of non-oral antihypertensive therapy.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Medical conditions requiring mandatory continuation of antihypertensive therapy for indications other than blood pressure control, precluding medication reduction or withdrawal.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Physical limitation preventing participation in light-to-moderate intensity physical activity.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Body mass index (BMI) \\\u003C 18.5 kg\u002Fm² or clinical diagnosis of malnutrition. \\\u003Cbr\\>\\\u003Cbr\\> Hospitalization for any cardiovascular cause within 12 months prior to enrollment.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Pregnancy, breastfeeding, or planned pregnancy during the study period. \\\u003Cbr\\>\\\u003Cbr\\> Participation in another interventional clinical study. \\\u003Cbr\\>\\\u003Cbr\\> Cognitive impairment, dementia, severe psychiatric disorder, or other condition that prevents adherence to study procedures or reliable communication with the research team.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Alcohol or illicit substance abuse within the previous 12 months. \\\u003Cbr\\>\\\u003Cbr\\> Any medical condition that, in the investigator's opinion, compromises participant safety or the feasibility of medication deprescribing.","40 Years",{"count":86,"type":21},240,[58],"The REMIDEP-HTA trial is a multicenter randomized controlled study designed to evaluate whether a structured approach combining an intensive lifestyle intervention with a systematic deprescribing algorithm can achieve clinical remission of essential hypertension.\n\n\\\u003Cbr\\>\\\u003Cbr\\>\n\nThe intervention integrates a 12-week high-intensity behavioral program focused on whole-food plant-based nutrition, progressive physical activity, sleep hygiene, and stress management, together with a hierarchical, safety-centered medication tapering protocol for antihypertensive therapy.\n\n\\\u003Cbr\\>\\\u003Cbr\\>\n\nThe study aims to determine whether remission can be achieved through a standardized and monitored strategy that prioritizes clinical safety during medication withdrawal.",[26],[25,91,92,82,93],"Remission","Lifestyle Medicine","Deprescribing Algorithm","2026-02-13",{"date":96,"type":36},"2026-02-20",{"date":98,"type":21},"2026-04",{"date":100,"type":21},"2026-12",{"name":102,"class":75},"Evelyn Vanina Re",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":56,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100625344","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-3-and-br1015-2-under-fed-conditions-100625344","NCT07421414","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions","A Randomized, Open-label, Fed, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-3\" and \"BR1015-2\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Subjects with a body mass index (BMI) of more than 18.0 kg\u002Fm² and less than 30.0 kg\u002Fm² at the screening visit.\n* Subjects who provide written informed consent voluntarily after receiving and understanding sufficient explanation regarding the purpose and procedures of the clinical trial, the characteristics of the investigational product, and the expected adverse events.\n* Subjects who agree to use a highly effective method of contraception, excluding hormonal contraceptives, from the time of signing the written informed consent form until 14 days after the last administration of the investigational product, and who agree not to donate sperm or ova during this period. This requirement applies to the subject and, as applicable, to their spouse or sexual partner in order to prevent pregnancy.\n\nExclusion Criteria:\n\n* Subjects who have taken drugs that induce or inhibit metabolizing enzymes, such as barbiturates, within 30 days prior to the first administration of the investigational product, or who have taken any prescription drugs, over-the-counter drugs (OTC), herbal medicines, or dietary supplements within 10 days prior to the first administration that may interfere with the conduct of the study (however, participation may be allowed considering the pharmacokinetics and pharmacodynamics, including potential interactions with the investigational product and the half-life of concomitant drugs).\n* Subjects with a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs (except for simple appendectomy or hernia surgery).\n* Subjects who have participated in other clinical trials (including bioequivalence studies) and received investigational products within 6 months prior to the first administration of this study. For this criterion, the 6-month period is counted from the last administration date of the investigational product in the previous study.\n* Subjects who are unable to discontinue consumption of foods that may affect the absorption, distribution, metabolism, or excretion of the investigational product (e.g., raw grapefruit, grapefruit juice, or foods containing grapefruit) from 48 hours prior to the first administration of the investigational product until the collection of the last pharmacokinetic blood sample.\n* Subjects who, for reasons other than those specified in the inclusion and exclusion criteria above, are judged by the principal investigator (or a sub-investigator delegated by the principal investigator) to be unsuitable for participation in the clinical trial.\n* Female subjects who are pregnant, suspected of being pregnant, or currently lactating.",true,"19 Years",{"count":113,"type":21},48,[115],"PHASE1","The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions",[26],"2026-02-12",{"date":120,"type":36},"2026-02-19",{"date":122,"type":21},"2026-04-19",{"date":124,"type":21},"2026-06-17",{"name":126,"class":127},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":56,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100625343","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-3-and-br1015-2-under-fasting-conditions-100625343","NCT07421401","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions","A Randomized, Open-label, Fasting, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-3\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":135,"type":21},58,[115],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions",[26],{"date":120,"type":36},{"date":141,"type":21},"2026-04-13",{"date":143,"type":21},"2026-06-11",{"name":126,"class":127},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":56,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100625341","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-1-and-br1015-2-under-fasting-conditions-100625341","NCT07421375","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions","A Randomized, Open-label, Fasting, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-1\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":135,"type":21},[115],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions",[26],{"date":120,"type":36},{"date":157,"type":21},"2026-04-02",{"date":159,"type":21},"2026-05-31",{"name":126,"class":127},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":56,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100625342","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-the-safety-after-administration-of-br1015-a-and-co-administration-of-br1015-1-and-br1015-2-under-fed-conditions-100625342","NCT07421388","A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions","A Randomized, Open-label, Fed, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of \"BR1015-A\" and Co-administration of \"BR1015-1\" and \"BR1015-2\" in Healthy Adult Volunteers",{"count":113,"type":21},[115],"The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions",[26],{"date":120,"type":36},{"date":173,"type":21},"2026-04-09",{"date":175,"type":21},"2026-06-07",{"name":126,"class":127},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":56,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":44},"100621668","phase-2-a-study-of-br1400-1-br1400-2-br1400-3-br1400-4-and-br1400-5-in-patients-with-essential-hypertension-100621668","NCT07373613","A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","Inclusion Criteria:\n\n\\\u003CScreening Visit (V1)\\>\n\nPatients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:\n\n* For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP \\\u003C 180 mmHg\n* For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP \\\u003C 180 mmHg\n\nFor patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study.\n\n\\\u003CBaseline Visit (V2)\\>\n\nPatients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:\n\n* For patients without cardiovascular disease: 140 mmHg ≤ MSSBP \\\u003C 180 mmHg\n* For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP \\\u003C 180 mmHg\n\nExclusion Criteria:\n\n* Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)\n* Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)\n* Patients with shock\n* Patients with orthostatic hypotension accompanied by symptoms",{"count":185,"type":21},330,[187],"PHASE2","The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.",[26],"2026-01-20",{"date":192,"type":36},"2026-01-28",{"date":194,"type":21},"2026-03-01",{"date":196,"type":21},"2027-02-01",{"name":126,"class":127},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":56,"phases":207,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100565564","phase-3-phase-3-trial-to-evaluate-the-efficacy-and-safety-of-ckd-202a-100565564","NCT06643819","Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","Inclusion Criteria:\n\n* Participants who are 19 years old or older.\n* Participants who have voluntarily decided to participate in this clinical trial and signed ICF.\n\nExclusion Criteria:\n\n* Participants with a history of secondary hypertension or suspected secondary hypertension.\n* Participants with a orthostatic hypotension.\n* Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.\n* Participants with type 1 diabetes or poorly controlled diabetes.\n* Participants who treated other clinical trial drugs within 4 weeks of screening visit.\n* Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening\n* Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug\n* Participants who are unable to participate in this clinical trial at the discretion of the investigator.",{"count":206,"type":21},324,[208],"PHASE3","Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)",[26],"2025-12-04",{"date":213,"type":36},"2025-12-11",{"date":215,"type":36},"2024-10-14",{"date":217,"type":21},"2026-12-31",{"name":219,"class":127},"Chong Kun Dang Pharmaceutical",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":56,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100614634","phase-1-safety-and-pharmacokinetics-study-of-bcd101-in-healthy-volunteers-100614634","NCT07282145","Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers","A Randomized, Double-blinded, Single\u002FMultiple Dosing, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BCD101 in Healthy Adult Volunteers","1. Inclusion Criteria\n\n   * Healthy adult volunteers aged 19 years or older at screening.\n   * Body weight ≥ 50.0 kg and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at screening.\n\n     \\* BMI (kg\u002Fm²) = weight (kg) \u002F {height (m)}²\n   * No congenital or chronic medical conditions requiring treatment, and no pathological signs or findings upon medical examination.\n   * Clinical laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram (ECG) results at screening indicate suitability for participation based on the characteristics of the investigational medicinal product.\n   * Fully understood the detailed explanation of this clinical trial, voluntarily agreed to participate, and provided written informed consent agreeing to comply with study requirements during the trial period.\n2. Exclusion Criteria\n\n   * History or current clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.\n   * Female subjects who are pregnant (urine hCG positive) or breastfeeding.\n   * History of hypersensitivity (e.g., anaphylaxis, angioedema) or clinically significant allergic reactions to the active ingredient, excipients of the investigational product, or other medications (e.g., aspirin, penicillin antibiotics, macrolide antibiotics).\n   * History of gastrointestinal diseases or surgeries that could affect absorption of the investigational drug (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis), except simple appendectomy or hernia surgery.\n   * Clinically significant abnormalities on 12-lead ECG at screening, including:\n\n     * QTc interval \\> 450 ms (males) or \\> 470 ms (females)\n     * PR interval \\> 200 ms\n     * QRS duration \\> 120 ms\n   * Clinically significant laboratory abnormalities at screening, including:\n\n     * Liver function tests (AST, ALT, ALP, γ-GT, total bilirubin) exceeding twice the upper limit of normal.\n     * Serum creatinine outside the reference range or estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73m² as calculated by the CKD-EPI formula.\n   * History of substance abuse or positive urine drug screening for abuse substances.\n\nVital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:\n\n* Systolic blood pressure ≤ 90 mmHg or ≥ 150 mmHg\n* Diastolic blood pressure ≤ 60 mmHg or ≥ 100 mmHg\n* Pulse rate ≤ 40 bpm or ≥ 100 bpm\n\n  * Evidence of orthostatic hypotension at screening.\n  * Use of enzyme-inducing or inhibiting drugs such as barbiturates within 1 month prior to first dosing.\n  * Abnormal diet or consumption of foods that could affect drug absorption, distribution, metabolism, or excretion.\n  * Use of prescription or herbal medications that may affect the investigational product's characteristics within 2 weeks prior to first dosing, or over-the-counter drugs or dietary supplements within 10 days prior to first dosing (except when judged by the investigator not to affect the pharmacokinetics of the investigational product).\n  * Participation in another clinical trial with investigational drug administration within 6 months prior to first dosing (the end date of participation is calculated as the day after the last dose of the previous trial).\n  * Whole blood donation within 2 months prior to first dosing, platelet donation within 1 month prior to first dosing, blood transfusion within 1 month prior to first dosing, or inability to abstain from blood donation from informed consent to PSV.\n  * Excessive alcohol consumption (more than 21 units per week; 1 unit = 10 g = 12.5 mL pure alcohol) within 6 months prior to first dosing or inability to abstain from alcohol from informed consent to PSV.\n  * Smoking more than 10 cigarettes per day within 3 months prior to first dosing or inability to abstain from smoking from 24 hours prior to first dosing until last blood sampling.\n  * Consumption of grapefruit-containing foods within 72 hours prior to first dosing or inability to abstain until PSV.\n  * Consumption of caffeine-containing foods or beverages (e.g., coffee, green tea, black tea, carbonated drinks, coffee milk, energy drinks) from 24 hours prior to first dosing until last blood sampling or inability to abstain.\n  * Engaging in strenuous exercise exceeding daily activity levels from 48 hours prior to first dosing until PSV or inability to refrain from such exercise.\n  * Planning to become pregnant or not using reliable contraception methods (e.g., hormonal contraceptives, intrauterine device, sterilization procedures, barrier methods) for self or partner from informed consent until 90 days after last dose of investigational product.\n  * Any other reasons deemed by the investigator to make the subject unsuitable for participation.",{"count":228,"type":21},56,[115],"A randomized, double-blinded, single\u002Fmultiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.\n\nThe primary objectives of this study are to determine:\n\n1. The safety and tolerability of BCD101 in healthy adult volunteers.\n2. The pharmacokinetic profile of BCD101 following single and multiple dosing.\n\nA control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.\n\nKey study activities include:\n\n1. Administration of single and multiple escalating doses of BCD101 and placebo under controlled conditions.\n2. Safety and tolerability assessments, including monitoring for serious adverse events and serious adverse drug reactions (Serious AEs\u002FADRs).\n3. Collection of blood samples for pharmacokinetic analysis.",[26],"2025-12-01",{"date":234,"type":36},"2025-12-15",{"date":236,"type":36},"2025-09-11",{"date":238,"type":21},"2026-04-30",{"name":240,"class":127},"Bichedam Co., Ltd.",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":56,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100596925","to-evaluate-the-safety-and-efficacy-of-a-single-use-ivus-ablation-for-primary-hypertension-100596925","NCT07051811","To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension","A Prospective, Multicenter, Blinded, Randomized Controlled Clinical Trial Evaluating the Safety and Efficacy of a Single-Use Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation System in the Treatment of Primary Hypertension","Inclusion Criteria:\n\n1. Aged ≥18 years and ≤75 years, regardless of gender.\n2. Documented history of primary hypertension.\n3. Stable use of at least two antihypertensive medications for a minimum of 4 consecutive weeks prior to randomization, specifically requiring a combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB) or a triple combination of ARB\u002FCCB plus a diuretic agent . After at least 4 consecutive weeks of screening, blood pressure must meet the following criteria:\n\n   1. Office systolic blood pressure (SBP) ≥150 mmHg and \\\u003C180 mmHg;\n   2. Office diastolic blood pressure (DBP) ≥90 mmHg;\n   3. 24-hour ambulatory systolic blood pressure ≥135 mmHg and \\\u003C170 mmHg.\n4. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to comply with clinical follow-up.\n\nExclusion Criteria:\n\n1. Unsuitable Renal Artery Anatomy for Treatment\n\n   1. Main renal artery diameter \\\u003C4 mm or length \\\u003C20 mm.\n   2. Accessory renal artery diameter ≥ 2 mm and \\\u003C4 mm.\n   3. Renal artery stenosis \\>50% in the main renal artery.\n   4. Renal artery aneurysm, fibromuscular dysplasia, or severe calcification.\n   5. Presence of a renal artery stent.\n   6. Single kidney.\n2. Estimated Glomerular Filtration Rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m².\n3. Diagnosis of Type 1 Diabetes Mellitus.\n4. Orthostatic Hypotension.\n5. Recent Vascular Events:Acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months prior to signing the informed consent form.\n6. Suspected Secondary Hypertension.\n7. Respiratory Support:a) Requirement for long-term oxygen support or mechanical ventilation (excluding nocturnal respiratory support for sleep apnea).\n8. Prior Renal Artery Denervation Procedure.\n9. Life Expectancy \\\u003C1 Year.\n10. Pregnancy, Lactation, or Plans to Become Pregnant Within 6 Months (for Females); Males Planning to Conceive Within 6 Months.\n11. Current Participation in Another Clinical Trial Without Completion of the Primary Endpoint.\n12. Allergy to Contrast Agents.\n13. Other Reasons Deemed by the Investigator to Make the Subject Unsuitable for Participation (e.g., Poor Compliance).","18 Years","75 Years",{"count":251,"type":21},213,[58],"This is a prospective, multicenter, blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the treatment of primary hypertension.",[26],"2025-07-02",{"date":257,"type":36},"2025-07-04",{"date":259,"type":36},"2025-02-25",{"date":261,"type":21},"2029-12-31",{"name":263,"class":127},"Lepu Medical Technology (Beijing) Co., Ltd.",18,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":53,"enrollmentInfo":273,"targetDuration":4,"studyType":56,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":44},"100583508","safety-and-efficacy-of-modulated-ultrasound-renal-denervation-for-htnfim-100583508","NCT06877234","Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）","An Exploratory Clinical Study on the Safety and Efficacy of the Ultrasonic Nerve Ablation System in the Treatment of Essential Hypertension","ModulationHTN1","Inclusion Criteria:\n\nMales or females aged 18 years old or above and 65 years old or below; Patients with essential hypertension; Patients who have been stably taking 2 or more antihypertensive drugs at conventional doses continuously for at least 4 weeks before enrollment, and whose blood pressure meets the following conditions: (1) The systolic blood pressure measured in the outpatient clinic is ≥150 mmHg and ≤180 mmHg, and the diastolic blood pressure measured in the outpatient clinic is ≥90 mmHg; (2) The systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) is between 135 mmHg and 170 mmHg; The course of hypertension is more than 6 months; The diameter of the renal artery evaluated by renal artery CTA is ≥3 mm and the length is ≥20 mm; The patient or his\u002Fher legal representative signs a written informed consent form approved by the ethics committee before screening;\n\nExclusion Criteria:\n\nComplicated with type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (defined as plasma Hb1Ac ≥ 10.0%); Estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m²; Previous implantation of an implantable cardioverter-defibrillator (ICD) or a pacemaker; History of myocardial infarction, syncope, intracerebral hemorrhage or cerebral infarction within 6 months before signing the informed consent form; Severe valvular heart stenosis; Any factors that may interfere with blood pressure measurement under any circumstances (for example, the patient has severe peripheral vascular disease, abdominal aortic aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia, severe anemia); Patients with sleep apnea syndrome; Females who are pregnant or breastfeeding, or those who have a plan to conceive within the next year; Other serious organic diseases with an expected lifespan of less than 12 months; Participation in other clinical trials before screening and not yet completed;\n\nPreoperative exclusion criteria based on CTA imaging:\n\na. Visual inspection shows that the diameter stenosis of the renal artery on either side \\> 50% or there is a renal artery aneurysm on either side; b. Previous history of renal artery interventional treatment; Other situations that the investigator deems unsuitable for enrollment.",{"count":274,"type":21},6,[58],"This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be included. After the subjects sign the informed consent form (ICF) approved by the ethics committee, they will enter the screening procedure. Subjects who meet the inclusion criteria and do not meet any of the clinical exclusion criteria will be enrolled after undergoing renal artery CTA angiography.\n\nAll patients will undergo clinical evaluation and blood pressure measurement during the operation, at the time of discharge, and at 1 month, 2 months, 3 months, and 6 months after the operation.\n\nIt is recommended that the anti-hypertensive medications used before the operation should not be changed within 6 months after the operation for the cases. When the systolic blood pressure (SBP) is ≥ 180 mmHg or there are clinical symptoms caused by hypertension, the drug dosage should be increased as a priority, and then the anti-hypertensive medications should be adjusted. When the systolic blood pressure (SBP) is ≤ 120 mmHg or there are clinical symptoms caused by a decrease in blood pressure, the anti-hypertensive medications should be reduced.",[26],"2025-06-16",{"date":280,"type":36},"2025-06-19",{"date":282,"type":36},"2024-08-08",{"date":284,"type":21},"2026-03",{"name":286,"class":127},"Shenzhen Pulsecare Medical Technology Co., Ltd.",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":56,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":44},"100550020","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-co-administration-of-ad-227a-and-ad-227b-100550020","NCT06441630","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B","A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Essential Hypertension\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patient with Secondary Hypertension\n* Other exclusions applied",{"count":295,"type":21},251,[208],"The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension",[26],"2025-02-02",{"date":301,"type":36},"2025-02-04",{"date":303,"type":36},"2024-07-31",{"date":305,"type":21},"2025-09",{"name":307,"class":127},"Addpharma Inc.",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":315,"targetDuration":4,"studyType":56,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":44},"100571186","phase-3-qr12000-compound-tablets-in-patients-with-moderate-to-severe-essential-hypertension-100571186","NCT06716970","QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril\u002Fvalsartan Tablets in Patients with Moderate to Severe Essential Hypertension","Inclusion Criteria:\n\n1. Subjects who can understand and are willing to complying with protocol requirement and sign the informed consent form.\n2. Man or woman aged 18 years to 75 years (inclusive), with BMI≤30 kg\u002Fm2.\n3. Patients with moderate to severe hypertension. Untreated patients must have an msSBP ≥ 160 mmHg and \\\u003C 190 mmHg at the screening and randomization visit; Treated patients must have an msSBP≥150 mmHg and \\\u003C180 mmHg or msSBP≥140 mmHg and \\\u003C170 mmHg at the screening visit based on numbers of antihypertensive and msSBP≥160 mmHg \\\u003C190 mmHg at the randomization visit; Patients must have an absolute difference of ≤20 mmHg in msSBP between randomization visit and the immediately preceding visit.\n4. Subjects who agree to use adequate contraception from 2 weeks prior to screening to 1 month after last dose.\n\nExclusion Criteria:\n\n1. History or evidence of a secondary form of hypertension.\n2. History of peripheral arterial occlusive disease and Raynaud's syndrome.\n3. History of hyperthyroidism.\n4. History of hypotension.\n5. History of angioedema, drug-related or otherwise.\n6. Suffered by severe cerebrovascular disease within 1 year prior to screening.\n7. Suffered by severe heart disease within 1 year prior to screening\n8. History of severe or malignant retinopathy.\n9. History of aortic aneurysm or dissection, cardiac surgery, or percutaneous coronary intervention within 1 year prior to screening.\n10. History of malignant tumor within 5 years prior to screening.\n11. Poorly controlled diabetes prior to screening\n12. History of severe autoimmune diseases.\n13. History of severe mental disorder.\n14. Clinically significant laboratory abnormalities.\n15. History of allergy to the test drug, active control drug, or drugs similar to the test drug and positive control drug or related excipients.\n16. Undergone gastrointestinal surgery that could significantly alter drug absorption, distribution, metabolism, and excretion, or with severe gastrointestinal diseases, dysphagia, or recurrent vomiting that causes difficulty in eating or taking medication.\n17. Intolerance to the run-in period.\n18. Poor medication compliance or other non-compliance during run-in period.\n19. Participated in any interventional clinical trial within 3 months prior to screening, plan to participate in another clinical trial during the period of this trial, or plan to participate in another clinical trial within 1 month after the end of this trial.\n20. History of alcohol abuse within 6 months prior to screening or evidence of drug abuse.\n21. Not agree or unable to comply with the restrictions on concomitant treatment during the study.\n22. Pregnancy test positive, lactating women, or women planning to become pregnant.\n23. High-altitude workers or large motor vehicle drivers and other professionals engaged in hazardous mechanical operations.\n24. Other conditions that by the investigator's discretion may interfere with efficacy or safety assessment of the study, or pose a great risk to the subject.",{"count":316,"type":21},810,[208],"The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril\u002Fvalsartan 200mg in patients with moderate to severe essential hypertension.",[26],"2024-12-03",{"date":322,"type":36},"2024-12-06",{"date":324,"type":21},"2024-12-30",{"date":326,"type":21},"2027-02-28",{"name":328,"class":127},"Wuhan Createrna Science and Technology Co., Ltd",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":56,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":44},"100504254","effects-of-remote-ischemic-conditioning-on-blood-pressure-in-older-patients-with-hypertension-100504254","NCT05845905","Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension","Inclusion Criteria:\n\n* 1\\) Age ≥65 years and ≤85 years, regardless of gender;\n* 2\\) History of essential hypertension and clinical systolic blood pressure ≥ 140 mmHg, regardless of whether they are receiving antihypertensive medication;\n* 3\\) Willing to participate and sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\) Secondary hypertension;\n* 2\\) Clinical blood pressure ≥ 180\u002F110 mmHg or 24-hour mean arterial pressure ≥ 170\u002F100 mmHg;\n* 3\\) Severe organ dysfunction or failure;\n* 4\\) Severe hematologic disorders or significant coagulation abnormalities;\n* 5\\) History of atrial fibrillation or myocardial infarction within 6 months;\n* 6\\) Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;\n* 7\\) Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc;\n* 8\\) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;\n* 9\\) Other conditions that the researchers think are not suitable for the project.","85 Years",{"count":337,"type":21},158,[58],"The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.",[26],"2024-10-01",{"date":343,"type":36},"2024-10-02",{"date":345,"type":36},"2023-05-10",{"date":347,"type":21},"2024-12-31",{"name":349,"class":75},"Yi Yang",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":56,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":44},"100559784","superselective-adrenal-arterial-embolization-for-refractory-hypertension-a-proof-of-concept-study-100559784","NCT06568640","Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study","Evaluation and Exploration of the Safety and Efficacy of Superselective Adrenal Arterial Embolization in Patients With Essential Refractory Hypertension: A Proof-of-Concept Study","SAAE-RH","Inclusion Criteria:\n\n* Age \\> 18 years, no gender restrictions;\n* Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times;\n* Duration of hypertension greater than 6 months;\n* Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Morning cortisol level \\\u003C 4.3 µg\u002FdL; estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m²; serum potassium level \\> 5.5 mmol\u002FL;\n* Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months;\n* Pregnant women or those planning to conceive within the next year;\n* Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization;\n* Adrenal mass with a diameter exceeding 2 cm;\n* Severe allergy to contrast agents;\n* Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.",{"count":359,"type":21},20,[58],"The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.",[26],[364,365,366],"Essential hypertension","Superselective adrenal arterial embolization","Interventional therapy","2024-08-22",{"date":369,"type":36},"2024-08-23",{"date":371,"type":36},"2024-08-01",{"date":373,"type":21},"2027-12",{"name":375,"class":75},"Second Affiliated Hospital of Nanchang University",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":384,"maxAge":53,"enrollmentInfo":385,"targetDuration":4,"studyType":56,"phases":387,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":44},"100506874","phase-4-study-of-bisoprolol-nerkardou---nerhadou-international-5-and-10-mg-oral-dissolvable-film-odf-treatment-in-egyptian-patients-with-essential-hypertension-100506874","NCT05880056","Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","A Prospective, Multicenter, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","BETTER","Inclusion Criteria:\n\n1. The participant is willing and able to give informed consent for participation in the trial.\n2. Male or Female, aged ≥ 21 and \\\u003C 65 years.\n3. The subject with Body mass index (BMI) greater than or equal to 18.5 and below 30 kg\u002Fm2\n4. Newly diagnosed hypertensive patients with grade 1 and 2 are defined according to the recent ESC\u002FESH guidelines as follows:\n\n   * Grade 1 hypertension: SBP 140 to 159mmHg and\u002For DBP 90 to 99mmHg\n   * Grade 2 hypertension: SBP 160 to 179mmHg and\u002For DBP 100 to 109mmHg at screening.\n5. Non-responders to the 1ST line of therapy for hypertension other than beta blocker and can be safely switched to Bisoprolol (Nerkardou) according to PI decision.\n6. Subject doesn't have other comorbidity according to the assessment of the medical history, electrocardiogram (ECG), echocardiogram vital signs, physical examination, and laboratory results.\n7. Subject with heart rate (HR) ≥ 80 (BPM) at baseline.\n8. Female subjects in childbearing period, and not on a reliable contraceptive method must adhere to the recommended contraceptive methods as detailed in Appendix I.\n9. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.\n\nExclusion Criteria:\n\n1. Grade III hypertension or malignant hypertension (Hypertensive crisis: Systolic over 180 and\u002For diastolic over 120).\n2. Subjects who are not legible to discontinue current antihypertensives such as calcium channel blockers (CCB), ACE- inhibitors, or diuretics for reasons other than hypertension, or responders to current therapy.\n3. Subjects with heart rates less than (\\\u003C)80 beats at rest.\n4. Subjects with renal impairment (serum creatinine \\> 2.0 milligram per deciliter \\[mg\u002FdL\\])\n5. Subjects with unrecovered pulmonary edema\n6. Subjects with a history of cardiovascular surgeries.\n7. Significant history of hypersensitivity to bisoprolol, amlodipine, other dihydropyridines, or any related products (including excipients of the formulations)\n8. Presence of diabetes mellitus\n9. History or presence of asthma\n10. Presence of significant gastrointestinal, liver, kidney disease, surgery, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects.\n11. Use of any enzyme-modifying drugs, including strong inhibitors of CYP enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, and human immunodeficiency virus \\[HIV\\] antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin, St. John's wort or other herbal medicine known with effect on CYP enzymes) within 28 days before Day 1 of this trial\n12. Acute conditions which might alter renal function (e.g., dehydration, severe infection)\n13. History of suicidal tendency, history of, or disposition to seizures, state of confusion, clinically relevant psychiatric diseases\n14. Positive pregnancy test (only for females of child-bearing potential), or females breastfeeding a child.\n15. Consumption of large quantities of methylxanthine-containing beverages (more than 600 mg caffeine\u002Fday: 1 cup (250 mL) of coffee contains approximately 100 mg of caffeine, 1 cup of black or green tea contains approximately 30 mg and 1 glass of cola contains approximately 20 mg caffeine)\n16. A participant with a life expectancy of fewer than 6 months, or inappropriate for the medication as defined in the Product Information such as acute heart failure or decompensation of heart insufficiency, that requires a therapy with inotropic agents; cardiogenic shock; AV block grade II or III, sick sinus syndrome, sinoatrial heart block; symptomatic bradycardia; symptomatic hypotonia; severe asthma bronchiolus or severe chronic obstructive airways disease; advanced stages of peripheral arterial disease or Raynaud's Syndrome; untreated pheochromocytoma, metabolic acidosis.\n17. Participants who have participated in another research trial involving an investigational product in the past 12 weeks.","21 Years",{"count":386,"type":21},406,[388],"PHASE4","The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 \\& 10 mg, and patients' compliance in the treatment of essential hypertension. This is a Phase IV, open-label, single-arm, prospective trial where subjects will receive:\n\n1. Bisoprolol (Nerkardou) at an initial dose of 5 (mg) milligrams once daily for 2 weeks.\n2. If the blood pressure would be greater than or equal to 130\u002F80 mmHg after 2 weeks, then the dose will be titrated to 10 mg once daily (non-responders). Dose-Titration will be done at any follow-up visit based on the response.\n3. The total duration of study treatment will be 12 weeks ±2 days, and the total sample size of the study will be 406 participants.",[26],"2024-08-15",{"date":393,"type":36},"2024-08-19",{"date":282,"type":36},{"date":396,"type":21},"2025-04-01",{"name":398,"class":127},"Genuine Research Center, Egypt",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":110,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":407,"conditions":408,"keywords":419,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100488296","a-multicentre-study-on-features-of-the-gut-microbiota-of-patients-with-critical-chronic-diseases-in-china-100488296","NCT05638269","A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China","Inclusion Criteria:\n\n1. aged 18-75 years;\n2. living in the province where the hospital is located in the last three years;\n3. with a medical diagnosis of one of the target diseases;\n4. willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. female in pregnancy or lactation(unless the subject is pregnant women);\n2. with medical diagnoses of other serious illnesses;\n3. with a history of bariatric surgery or intestinal resection, except for appendectomy；\n4. individual who was treated with drugs in the preceding 1 month, including antibiotics, metformin, statins, acid inhibitor, probiotics, and probiotics; individuals having consumed yogurt more than 3 times in the preceding 1 month; heavy drinkers who have consumed more than 4 taels of liquor or 1000ml of beer; frequent alcohol consumers who have drunk per week in the last month.",{"count":406,"type":21},12000,"The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of various critical chronic diseases, compare the similarities and differences of the microbiome signatures linked to different regions and diseases, and further investigate their impacts on microbiota-based diagnostic models.",[26,409,410,411,412,413,414,415,416,417,418],"Liver Cancer","Nasopharyngeal Cancer","Pancreatic Cancer","Lung Cancer","Chronic Kidney Diseases","Acute Coronary Syndrome","Epilepsy","Gastric Cancer","Primary Aldosteronism","Subclinical hypothyroïdism",[420,421,422,423,424,425],"cardiovascular disease","exctracoonic cancer","nervous system diseases","endocrine diseases","urological diseases","microbial dysbiosis","2024-07-26",{"date":428,"type":36},"2024-07-29",{"date":430,"type":36},"2022-03-01",{"date":432,"type":21},"2025-12",{"name":434,"class":75},"Zhujiang Hospital",50,{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":56,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":44},"100554635","phase-4-sacubitrilvalsartan-treats-patients-with-essential-hypertension-and-type-2-diabetic-nephropathy-100554635","NCT06501651","Sacubitril\u002FValsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril\u002FValsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study","Hyper-Save","Inclusion Criteria:\n\n* Age 18 years or older, no gender restriction;\n* Diagnosed with mild to moderate primary hypertension (140 ≤ SBP \\\u003C 180 mmHg and\u002For 90 ≤ DBP \\\u003C 110 mmHg), including newly diagnosed or inadequately treated patients (those who have not followed previous medical advice and have uncontrolled blood pressure according to the investigator);\n* Diagnosed with type 2 diabetes (according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)), and meeting the following conditions: a) Continuously on ≥ 1 glucose control medication regimens (which may include long-acting insulin) for at least 12 weeks before screening, with a stable treatment regimen (i.e., the same medication and dosage) for at least 28 days before screening, and maintaining this regimen during the study. At the investigator's discretion, the dose of supplemental short-acting insulin can be adjusted as needed to achieve adequate glucose control; b) HbA1c level ≤ 10.5% and fasting (≥ 8 hours) plasma glucose level ≤ 13.3 mmol\u002FL (if fasting glucose \\> 13.3 mmol\u002FL, the investigator may repeat the test to determine eligibility);\n* Urine albumin\u002Fcreatinine ratio (UACR) ≥ 30 mg\u002Fg in two measurements taken on separate days or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²;\n* Non-pregnant or fertile patients (male or female) using reliable contraception;\n* Female patients with potential for pregnancy must have a negative pregnancy test at screening;\n* Subjects must voluntarily agree to comply strictly with the study protocol requirements and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe hypertension, malignant hypertension, hypertensive emergencies, or hypertensive crises;\n* History or evidence of secondary hypertension within 12 months before screening, including but not limited to any of the following: renovascular hypertension, renal parenchymal hypertension, unilateral or bilateral renal artery stenosis, coarctation of the aorta, primary aldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension;\n* History of angioedema (drug-related or other causes) within 12 months before screening;\n* Presence of diabetic ketoacidosis;\n* History or evidence of secondary diabetes within 12 months before screening, including but not limited to any of the following: endocrine disorders causing carbohydrate metabolism disorders, pancreatogenic diabetes, hepatogenic diabetes, nephrogenic diabetes, etc.;\n* History of malignancy in any organ system (excluding localized basal cell carcinoma of the skin);\n* History of acute stroke, lacunar infarction, or dementia within 6 months before screening;\n* History of coronary artery bypass graft surgery or any percutaneous coronary intervention (PCI) within 6 months before screening;\n* Previously diagnosed or currently diagnosed heart failure (NYHA Class III-IV) or clinically significant valvular heart disease;\n* History or current diagnosis of cardiac abnormalities: (1) second or third-degree atrioventricular block without a pacemaker; (2) clinically significant arrhythmias, including atrial fibrillation with a ventricular rate ≥ 120 bpm; (3) family history of long QT syndrome or torsades de pointes ventricular tachycardia;\n* Chronic kidney disease stage 4 or higher (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), receiving renal dialysis, or history of kidney transplantation;\n* Significant abnormalities in laboratory tests, such as potassium levels \\> 5.5 mmol\u002FL or \\\u003C 3.5 mmol\u002FL, sodium levels \\\u003C 130 mmol\u002FL, liver function (ALT, AST) results \\> 3 times the upper limit of normal;\n* History of allergy to antihypertensive drugs such as ARBs, Angiotensin-Converting Enzyme (ACE) inhibitors, or renin inhibitors;\n* Clear history of intolerance to drugs similar to the study medication (e.g., ACE inhibitors, ARBs);\n* Use of traditional Chinese or Western medicines that could affect the study's efficacy during the study period (see appendix for list);\n* Any surgery or medical condition that significantly alters the absorption, distribution, metabolism, or excretion of any medication, including but not limited to the following: clinically significant gastrointestinal surgery within 12 months before the screening (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastroenterostomy, or gastric banding), current active inflammatory bowel disease or history of active inflammatory bowel disease;\n* Pregnant or breastfeeding women, or patients of childbearing potential unwilling or unable to use effective contraception during the study period;\n* Participation in another clinical study using any investigational drug or observational study within 30 days before screening;\n* Other conditions that, in the investigator's judgment, may affect the conduct of the clinical study or the determination of study results.",{"count":445,"type":21},297,[388],"This study aims to compare the efficacy and safety of Sacubitril\u002FValsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.",[26,449,450],"Type 2 Diabetes","Nephropathy",[364,452,450,453],"Type 2 diabetes","Sacubitril\u002FValsartan","2024-07-09",{"date":456,"type":36},"2024-07-15",{"date":371,"type":21},{"date":459,"type":21},"2025-04-10",{"name":461,"class":75},"Sichuan Academy of Medical Sciences"]